These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24586842)

  • 41. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
    Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
    Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
    Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
    J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
    Goldberg SB; Oxnard GR; Digumarthy S; Muzikansky A; Jackman DM; Lennes IT; Sequist LV
    Oncologist; 2013; 18(11):1214-20. PubMed ID: 24072220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
    Bronte G; Franchina T; Alù M; Sortino G; Celesia C; Passiglia F; Savio G; Laudani A; Russo A; Picone A; Rizzo S; De Tursi M; Gambale E; Bazan V; Natoli C; Blasi L; Adamo V; Russo A
    Oncotarget; 2016 Jun; 7(24):35803-35812. PubMed ID: 26993607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.
    Shaozhang Z; Ming Z; Haiyan P; Aiping Z; Qitao Y; Xiangqun S
    Med Oncol; 2014 May; 31(5):926. PubMed ID: 24748405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
    Sequist LV; Joshi VA; Jänne PA; Muzikansky A; Fidias P; Meyerson M; Haber DA; Kucherlapati R; Johnson BE; Lynch TJ
    Oncologist; 2007 Jan; 12(1):90-8. PubMed ID: 17285735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
    Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC; Yang JC
    Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
    Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
    PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
    Wang Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
    Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
    Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
    van Zandwijk N; Mathy A; Boerrigter L; Ruijter H; Tielen I; de Jong D; Baas P; Burgers S; Nederlof P
    Ann Oncol; 2007 Jan; 18(1):99-103. PubMed ID: 17060486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.